MedTrace Logo

Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

NCT03251547 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2018-10-10

No results posted yet for this study

Summary

This is a retrospective descriptive study, to study the treatment indications, changes in transfusion need, coagulation profiles changes and clinical outcome (survival, complication) of non-haemophiliac patients who received activated factor seven (rFVIIa / NovoSeven®) during massive bleeding in Hospital Universiti Sains Malaysia (HUSM)

Conditions

  • Massive Hemorrhage
  • Massive Blood Loss
  • Massive Blood Transfusion; Thrombocytopenia

Interventions

DRUG

NovoSeven

To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding

Sponsors & Collaborators

  • Universiti Sains Malaysia

    lead OTHER

Principal Investigators

  • Chong Soon Eu, MD, MMed · Universiti Sains Malaysia

  • Nurfatin Mohd Shah, BSc · Universiti Sains Malaysia

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-21
Primary Completion
2017-10-15
Completion
2017-11-15
FDA Drug
Yes

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03251547 on ClinicalTrials.gov